The latest research progress for the evaluation and management of EGFR tyrosine kinase inhibitor-associated skin rash in patients with non-small-cell lung cancer

摘要：

Non-small-cell lung cancer (NSCLC) is one of the most common malignant tumors and the leading cause of cancer-related mortality in worldwide.Epidermal growth factor receptor (EGFR), as an important molecular target, is usually over-expression associated with cancer development and progression of some kinds of malignancies.In recent years, EGFR tyrosine kinase inhibitors (EGFR-TKIs) such as Erlotinib/Gemcitabine/Icotinib, has proven efficacy from first-line treatment to third-line treatment and be used to treat a wide range of patients with NSCLC, including some patients that have a lower likelihood of EGFR mutation.

关键词： NSCLC EGFR-TKI targets therapy skin rash

作者: Xiaodong Xie Fang Guo

作者单位: The Department of Oncology, General Hospital of Shenyang Military Region

会议类型: 国内会议

会议名称: 第六届中国肿瘤内科大会

会议地点: 北京

会议语种:英文

页码: 56-56

在线出版日期: 2012-06-28（万方平台首次上网日期，不代表论文的发表时间）